Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

This is a multicenter, randomized, open-label, Phase 3 study

Trial Details

NCT ID
NCT06008119
Phase
PHASE3
Sponsor
Shanghai Kechow Pharma, Inc.
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Tunlametinib plus Vemurafenib
  • Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Inclusion Criteria:
  • Before study entry, written informed consent must be obtained from the patient prior to performing any study-related procedures.
  • Male or female patients with 18 to 70 years of age at time of informed consent;
  • Histological or cytologically confirmed metastatic CRC

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →